EpiEndo Pharmaceuticals ehf got the green light for a Phase IIa COPD trial with its non-anbibiotic macrolide EP395
Tag Archive for: Drug development
Jolt Capital contributed $20m to the BC Platforms’ data footprint expansion on November 8th.
EpiEndo Pharmaceuticals ehf got the green light for a Phase IIa COPD trial with its non-anbibiotic macrolide EP395
Jolt Capital contributed $20m to the BC Platforms’ data footprint expansion on November 8th.